Humacyte's Symvess Debut: A Milestone With Lingering Concerns (Rating Downgrade)
Humacyte stock has dropped 46% since July, mainly due to FDA review delays. Check out why I downgraded HUMA stock from "buy" ...
Too Old to Operate9 小时
Autologous Skin Cell Suspension for Treating Stable Vitiligo Lesions
The following is a summary of “Effective and durable repigmentation for stable vitiligo: A randomized within-subject ...
Philippine Daily Inquirer11 小时
Mysterious stem cells: ASC infusion process (2)
I explained last Monday that there are, in general, two types of stem cell therapies. I started with the autologous stem cell ...